ColoRectal Cancer Clinical Trial
Official title:
PROSPR Project 2: Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies
Verified date | May 2018 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall goal of the Parkland-UT Southwestern Population-based Research Optimizing
Screening through Personalized Regimens (PROSPR) is to optimize colon cancer screening
through personalized regimens in our integrated safety-net clinical provider network, which
serves a large and diverse population of under- and un-insured patients in Dallas.
Together, three research projects will assess clinic, system, and organizational factors
associated with over-, under- and guideline-based screening among this important population
and will compare benefits, harms, and costs of strategies for facilitating optimized
screening regimens. Our theme of optimizing colorectal cancer screening in a safety-net
clinical provider network brings together several components. Its focus on colorectal cancer
(CRC) screening which is important, because CRC is the second cancer killer in the US while
being the only major cancer for which optimized screening results in primary prevention.
Despite this strong potential benefit, CRC screening remains suboptimal overall, and
especially among low-income and minority individuals served by safety-nets. Safety-net
networks therefore offer tremendous potential for CRC prevention and control, but numerous
factors at the clinics-, system-, and organization-level influence their ability to provide
optimized care.
Status | Active, not recruiting |
Enrollment | 6000 |
Est. completion date | January 2019 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 64 Years |
Eligibility |
Inclusion Criteria: - Patients (names and contact information selected from the Parkland-UT Southwestern PROSPR Center database IRB #082011-040) who are not up-to-date with CRC screening. - Age 50-64 years. - Seen one or more times at a Parkland primary care clinic - Participants in Parkland's medical assistance program for the uninsured - Participants in Parkland Health Plus (Parkland Health Plus insurance and greater than 1 primary care visit within one year (Index Year)). - Patients who obtain coverage through the Affordable Care Act's Health Insurance Marketplace after randomization will not be removed from the study. - Both English and Spanish speakers will be eligible for participation. - No racial or ethnic group will be excluded from participation. Exclusion Criteria: - Ip-to-date with CRC screening, defined by: a) Colonoscopy in the last 10 years, b) Sigmoidoscopy in the last 5 years, or c) Stool blood test (FIT) in the last year. - Patients with a prior history of CRC, inflammatory bowel disease, or colon polyps, or who do not have an address or phone number on file. - Incarcerated individuals will also be excluded. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FIT vs. Colonoscopy | Compare benefits, harms, and costs of a FIT strategy versus a Colo strategy for CRC screening among patients not up-to-date with screening. | 2 years | |
Primary | FIT vs. Usual Care | Compare benefits, harms, and cost of a) the FIT strategy versus Usual Care and b) the Colo strategy versus Usual Care. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |